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Abstract
Background: Appropriate long-term drinking of red wine is associated with a reduced risk of cardiovascular disease. 
Resveratrol, a well-known SIRT1 activator is considered to be one of the beneficial components contained in red wine, 
and also developed as a drug candidate. We previously demonstrated that resveratrol protects brain against ischemic 
stroke in mice through a PPARα-dependent mechanism. Here we report the different effects of the oligomers of 
resveratrol.
Methods: We evaluated the activation of PPARs by ε-viniferin, a resveratrol dimer, and vaticanol C, a resveratrol 
tetramer, in cell-based reporter assays using bovine arterial endothelial cells, as well as the activation of SIRT1. 
Moreover, we tested the metabolic action by administering vaticanol C with the high fat diet to wild-type and PPARα-
knockout male mice for eight weeks.
Results: We show that vaticanol C activates PPARα and PPARβ/δ in cell-based reporter assays, but does not activate 
SIRT1. ε-Viniferin shows a similar radical scavenging activity as resveratrol, but neither effects on PPARs and SIRT-1. 
Eight-week intake of vaticanol C with a high fat diet upregulates hepatic expression of PPARα-responsive genes such as 
cyp4a10, cyp4a14 and FABP1, and skeletal muscle expression of PPARβ/δ-responsive genes, such as UCP3 and PDK4 
(pyruvate dehydrogenase kinase, isoform 4), in wild-type, but not PPARα-knockout mice.
Conclusion: Vaticanol C, a resveratrol tetramer, activated PPARα and PPARβ/δ in vitro and in vivo. These findings 
indicate that activation of PPARα and PPARβ/δ by vaticanol C may be a novel mechanism, affording beneficial effects 
against lifestyle-related diseases.
Background
Prevention of lifestyle-related diseases, such as cardiovas-
cular disease, diabetes, and stroke, has become of world-
wide interest. In such lifestyle-related matters, people pay
attention not only to drugs, but also to the functionality
of natural chemicals contained in food and drink, such as
polyphenols and their polymers. In this context, resvera-
trol, a phytoalexin and antioxidant polyphenol included
in red wine and various plants, is one of the most attrac-
tive compounds, and experimental data on resveratrol
has been accumulating [1,2]. The polymers of resveratrol
are also known phytoalexins and antioxidants. The res-
veratrol dimer, ε-viniferin, is a major phytoalexin in
response to UV-C irradiation [3] and has been reported
to be an antioxidant [4]. The resveratrol tetramer, vati-
canol C, exhibited a more potent cytotoxic effect against
human cultured cancer cells than resveratrol [5-7]. By
screening 20 derivatives of resveratrol, vaticanol C was
found to have the strongest suppressive activity of cell
growth in colon cancer cell lines [6]. However, the molec-
ular mechanisms for these actions remain to be deter-
mined.
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We demonstrated that resveratrol activates peroxisome
proliferator-activated receptor (PPAR) α and γ in cell-
based reporter assays and protects the brain against isch-
emic stroke in mice through a PPARα-dependent mecha-
nism [8]. PPARs are members of nuclear receptor family
of ligand-dependent transcription factors [9]. The PPAR
subfamily consists of three isotypes, PPARα, β/δ, and γ,
which play various roles in lipid and carbohydrate metab-
olism, cell proliferation and differentiation, and inflam-
mation and are considered to be molecular targets
against lifestyle-related diseases [10,11]. For example,
PPARα and γ agonists, such as fibrates and thiazolidine
derivatives, are used to treat dyslipidemia and diabetes,
respectively. Moreover, eicasapentaenoic acid, a natural
ligand for PPARα, has been used as a hypolipidemic drug
and has been reported to lower plasma and liver choles-
terol levels in a PPARα-dependent manner [12]. Thus, we
have focused on PPARs as possible molecular targets of
resveratrol in preventing lifestyle-related diseases, while
others have studied SIRT1, a NAD+-dependent protein
deacetylase, and PGC-1α [13-17].
In the present study, we evaluated the activation of
PPARs, antioxidant, and SIRT1-activator properties of
resveratrol, ε-viniferin, and vaticanol C and found that
vaticanol C activates PPARα and PPARβ/δ in cell-based
reporter assays, but does not have antioxidant or SIRT1-
activator properties. Moreover, 8-week intake of vati-
canol C with a high fat (HF) diet upregulates hepatic
expression of PPARα-responsive genes and skeletal mus-
cle expression of PPARβ/δ-responsive genes in wild-type,
but not PPARα-knockout mice. These findings indicate
that activation of PPARα and PPARβ/δ by vaticanol C
may provide beneficial effects against lifestyle-related dis-
eases.
Methods
Reagents
ε-Viniferin, a resveratrol dimmer, and vaticanol C, a res-
veratrol tetramer, were isolated from the genus belonging
to Vatica, Shorea, and Vateria (Dipterocarpaceae) as
described previously [5,6]. A stock solution of these com-
pounds was prepared in 10 mM dimethyl sulfoxide
(DMSO), and was further diluted to the working concen-
tration before use.
Cell Culture
Bovine arterial endothelial cells (BAEC) [8,18] were
grown in DMEM supplemented with 10% fetal calf serum
and 50 μM 2-mercaptoethanol.
RNA Extraction and Analysis
Total RNA was isolated using the acid guanidinium thio-
cyanate procedure, and was analyzed for gene expression
via real-time quantitative RT-PCR (Mx3005, Stratagene)
as described previously [18]. The primer pairs for genes
in this study and their cycling conditions are shown in
Additional file 1. Expression levels of each mRNA were
normalized to those of 36B4 mRNA.
Transcription Assays
I n  t h e  c a s e  o f  a c t i v a t i o n  a s s a y  f o r  P P A R α ,  B A E C  w a s
transfected with 0.15 μg of tk-PPREx3-Luc reporter plas-
mid, 0.15 μg of human PPARα expression vector pGS-
hPPARα (Invitrogen, GeneStorm™ clone L02932) and
0.02 μg of pSV-βgal as described previously using Trans
IT-LT-1 (Mirus) [19]. In the activation assay for PPARβ/δ
and γ, their expression vectors pCMX-hNUCI (PPAR β/
δ) and pCMX-hPP ARγ1 were used for the transfection,
instead of the human PPARα expression vector [18]. The
transfected BAEC were harvested, lysed, and assayed for
both luciferase and β-galactosidase activities. The results
are represented as relative luciferase activities, which
were normalized against the β-galactosidase standard.
Transfection efficiency of BAEC is over 20% estimated by
cotransfection of pEGFP-N1, an expression vector for
Green Fluorescent Protein. pCMX-hNUCI and pCMX-
hPPARγ1 were human PPARγ1 and PPARβ/δ expression
vectors under control of a cytomegalovirus promoter
[18]. In the positive control experiments, selective activa-
tors of PPARs, such as Wy-14643 (α), GW501516 (β/δ),
and pioglitazone (γ), had PPARα, β/δ, and γ agonistic
activities, respectively [18].
DPPH Radical Scavenging and SIRT1 Activation Assays
Resveratrol and its derivatives were dissolved in DMSO
to prepare samples at 500 μM. Twenty microliters of each
sample, 80 μL of 0.1 M Tris HCl buffer (pH 7.4), and 100
μL of 500 μM 1,1-diphenyl-2-picryl-hydrazyl (DPPH)
solution were mixed well and incubated at room temper-
ature for 20 min, then the absorbance was recorded at
540 nm with a plate reader (Immuno mini NJ2300, Nal-
gene) as described [20]. Trolox (6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid) was the reference
antioxidant, used as a positive control, and each result is
expressed as the equivalent per mole of trolox from the
percentage decrease with respect to the negative control
value. Data are presented as mean ± SD (n = 3).
The Fluor de Lys fluorescence assay for in vitro SIRT1
activity was performed by the SIRT1 activity assay kit
(BIOMOL, catalog number AK-555), according to the
manufacturer's instructions. Fluorescent intensity was
measured using an Infinite F200 microplate fluorometer
(TECAN). DMSO was used as a negative control and also
as a solvent for resveratrol and its derivatives to a final
concentration of 100 μM in the assay buffer.Tsukamoto et al. Nutrition & Metabolism 2010, 7:46
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Animal Experiments
Male 12-week-old 129SV-strain (wild-type) and PPARα-
knockout (129SV background) mice were obtained by
Jackson laboratory (USA). These mice were housed in a
room at 24 ± 2°C with a 12/12 h light-dark cycle, and fed a
HF diet containing 60% energy as fat, supplemented with
vaticanol C (0 and 0.04%) for 8 weeks. Diet and water
were available ad libitum. After 8 weeks of feeding, the
mice were sacrificed under diethyl ether anesthesia to
obtain tissues. Liver and skeletal muscle were stored in
RNAlater™ solution (Ambion, USA) at -30°C until gene
expression analysis. These experimental procedures were
approved by the Animal Care Committee of Nara
Women's University.
Statistical analyses
All results are expressed as means ± SD. Comparisons
between groups were performed with the unpaired t test.
Values were deemed to be statistically significantly differ-
ent at p < 0.05.
Results
Activation of PPARs In Vitro by Resveratrol and Vaticanol C 
but not by ε-Viniferin
Resveratrol activated PPARα and γ in our cell-based assay
using bovine arterial endothelial cells (BAEC) [8]. In this
assay system, we also confirmed that selective activators
of PPARs, such as Wy-14643 (α), GW501516 (β/δ), and
pioglitazone (γ), had PPARα, β/δ, and γ agonistic activi-
ties, respectively [18]. Using this assay system, we evalu-
ated the activation of PPARs by resveratrol, ε-viniferin,
and vaticanol C (Figure 1A). Activation of PPARα and β/δ
were observed by resveratrol and vaticanol C, whereas
only resveratrol activated PPARγ (Figure 1B). These effi-
cacies of resveratrol and vaticanol C on PPARα and β/δ
were roughly similar to those of selective activators such
as Wy-14643 and GW501516, respectively [18]. Remark-
ably, at lower concentrations, 1.25-5 μM, vaticanol C was
a more potent activator for PPARα than resveratrol. On
the other hand, ε-viniferin showed no agonistic activity
for PPARs. At a concentration of 10 μM, resveratrol
showed triple agonistic activities for α, β/δ and γ, whereas
vaticanol C showed dual agonistic activities for α and β/δ
Figure 2A). These properties of resveratrol and vaticanol
C will provide beneficial effects against lifestyle-related
disease since several drugs were reported to have similar
properties.
No Correlation with Resveratrol or its Derivatives between 
Activation of PPARs and Radical-Scavenging Activities
Next, we evaluated resveratrol and its derivatives for their
radical-scavenging activity using DPPH, a stable free rad-
ical [20]. As shown in Figure 2B, resveratrol and ε-vin-
iferin showed similar radical-scavenging activities,
comparable to the positive control radical scavenger,
trolox, a water-soluble derivative of vitamin E. On the
other hand, vaticanol C showed no radical scavenging
activity (Figure 2B), indicating that there was no correla-
tion between agonistic activities for PPARs and radical-
scavenging activity.
No Activation of SIRT1 by Vaticanol C or ε-Viniferin
Because resveratrol has been reported to be an activator
for SIRT1 [13], we evaluated the activation of SIRT1 by ε-
viniferin and vaticanol C. As a positive control, resvera-
trol activated SIRT1; however, ε-viniferin and vaticanol C
did not (Figure 2C). Rather, vaticanol C seemed to inhibit
SIRT1 activity in this assay. Taken together, vaticanol C, a
resveratrol tetramer, is a dual agonist for PPARα and β/δ,
but not a radical scavenger and not a SIRT1 activator.
Vaticanol C Administration Induces Expression of PPAR-
dependent Genes
The metabolic actions of vaticanol C were then evaluated
by administering the compound by food admixture (0
and 0.04%) to wild-type and PPARα-knockout male mice
c h a l l e n g e d  w i t h  t h e  H F  d i e t  f o r  8  w e e k s .  D u r i n g  t h i s
experiment, there was no statistically significant differ-
ence in body weight between the eight groups.
We evaluated the effects of vaticanol C administration
on the expression of PPAR-dependent genes in wild-type
and PPARα-knockout mice. In the liver, expression of
cyp4a10, cyp4a14 and fatty acid binding protein 1
(FABP1) was induced by 0.04% vaticanol C in the wild-
type, but not in the knockout mice (Figure 3A). In the
positive control, expression of these genes was also
induced by 0.02% fenofibrate, a PPARα agonist, in the
wild-type mice (Figure 3B). On the other hand, expres-
sion of FGF21, a PPARα-responsive protein, was not
induced by 0.04% vaticanol C, and by 0.02% fenofibrate
(Figure 3A, B), which may be due to feedback control of
the PPARα-FGF21 endocrine pathway [21,22]. Expres-
sion of other PPARα-dependent genes, such as acyl-CoA
oxidase (Acox1) and long-chain type acyl-CoA dehydro-
genase (LCAD) was induced by 0.02% fenofibrate (Figure
3B) but not 0.04% vaticanol C (Figure 3A) in the wild-
type mice, and was reduced in the knockout mice (Figure
3A). We also tested fenofibrate in PPARα-knockout mice
on high fat diet (n = 2) or on normal fat diet (n = 4); how-
ever, no induction of PPARα-responsive genes was
observed (data not shown), which is similar to the results
of vaticanol C with a HF diet. The discrepancies between
fenofibrate and vaticanol C were unknown, but may be
involved in other regulating factors for gene expression.
In this point, we found that 0.04% resveratrol treatment
with a normal diet, but not with a HF diet, showedTsukamoto et al. Nutrition & Metabolism 2010, 7:46
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induced expression of Acox1 and LCAD (manuscript in
preparation), which are not induced by vaticanol C treat-
m e n t  w i t h  a  H F  d i e t  ( F i g u r e  3 A ) .  I n  s k e l e t a l  m u s c l e s ,
expression of PPARβ/δ-dependent genes, such as UCP3
and PDK4 [23,24], was induced by vaticanol C in wild-
type, but not in knockout mice (Figure 3A).
Discussion
Resveratrol is known to be a SIRT1-activator. However,
various effects of resveratrol are not explained by activa-
tion of SIRT1 alone. We found that resveratrol is an acti-
vator not only for PPARα and γ [8], but also for PPARβ/δ
(Figure 1B) in this report. Moreover, vaticanol C, a res-
veratrol tetramer, is an activator for PPARα and β/δ in
cell-based reporter assays (Figure 1B), which is confirmed
by induced expression of PPAR-responsive genes in wild-
type, but not PPARα-knockout, mice (Figure 3A). At
lower concentrations of 1.25-5 μM, vaticanol C showed
higher PPARα-agonistic activity than resveratrol. How-
ever, at 10 μM, resveratrol showed higher activity than
vaticanol C (Figure 1A), and this activity of resveratrol
was dose-dependent, at less than 40 μM (data not
shown). Previously, we found that expression of COX-2,
an inducible key enzyme for prostaglandin synthesis, was
regulated by 15d-PGJ2, a natural ligand for PPARγ [19].
Interestingly, vaticanol C as well as resveratrol [25] sup-
pressed the expression of COX-2 in several kinds of
tumor cell lines (data not shown) whereas vaticanol C is
not an activator for PPARγ.
Vaticanol C did not activate SIRT1 whereas resveratrol
activated SIRT1 by the assay utilizing a fluorophore-con-
taining peptide (Figure 2C). Recent report showed that
this assay was not suitable to direct measurement of the
SIRT1 activity and that resveratrol did not activate SIRT1
in the assay without the fluorophore-containing peptide
[26]. Therefore, by the different assay system, we may
confirm that vaticanol C is not activator for SIRT1. Taken
together, vaticanol C is a dual activator for PPARα and β/
δ, whereas resveratrol is a triple activator for PPARα, β/δ
and γ, indicating that vaticanol C is thought to be differ-
ently effective on lifestyle-related diseases, compared
with resveratrol.
A resveratrol dimer, ε-viniferin has radical-scavenging
activity, but does not have agonistic activity for PPARs or
SIRT1, which differs from resveratrol and vaticanol C
(Figure 2). These differences indicate the importance of
Figure 1 Activation of PPARs by Resveratrol, ε-Viniferin and Vaticanol C. (A) Structures of resveratrol (monomer), ε-viniferin (dimer) and vaticanol 
C (tetramer). (B) Activation of PPARα, β/δ, and γ was evaluated by transfection assays using BAEC with PPRE-luc together with GS-hPPARα, pCMX-NUC1 
or pCMX-hPPARγ1, respectively. Results are presented as relative luciferase activities obtained by dividing the normalized luciferase activity from the 
reporter vector PPRE-luc. *, P < 0.05, **, P < 0.01 compared with the value of cells treated with ethanol (control) by unpaired t-test (n = 3).Tsukamoto et al. Nutrition & Metabolism 2010, 7:46
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the structure of these chemicals. Concerning the binding
pocket of PPARα, the molecular sizes of resveratrol and
vaticanol C are smaller and larger than those of synthetic
PPAR agonists such as fenofibrate, respectively. Resvera-
trol but not vaticanol C activates PPAR γ, indicating the
importance of the structure of these molecules in the
binding pocket of PP ARs. It was reported that a single
amino acid, which was Tyr in PPARα and His in PPARγ,
imparted subtype selectivity for both thiazolidinedione
and nonthiazolidinedione ligands [27]. We need more
experimental data to discuss about these points including
the possibility of indirect activation of PPARs by resvera-
trol and vaticanol C.
There are distinct expression patterns of PPAR-respon-
sive genes in the liver and skeletal muscle, indicating that
PPAR-responsive genes are controlled in a tissue-specific
manner (Figure 3A). In this context, especially in skeletal
muscles, vaticanol C upregulates expression of PPARβ/δ-
responsive genes, such as UCP3 and PDK4, in the wild-
type, but not PPARα-knockout mice, indicating that
PPARα is also involved in the expression of PPARβ/δ-
responsive genes.
Resveratrol has been reported to prevent body weight
gain with a HF diet [15]. No such effect on body weight
was observed after vaticanol C treatment. We found that
129SV mice used in our study showed milder body
weight gain with a HF diet, versus the C57/black strain
mice used in several reports. This difference on body
weight gain will be due to the different strains between
129SV and C57/black. These genetic differences are also
usual common in human genomes. To address these
questions, we are studying on the molecular mechanism
involved in the physiological differences between 129SV
and C57/black mice.
Conclusion
Vaticanol C, a resveratrol tetramer, activates PPARα and
PPARβ/δ in cell-based reporter assays, but does not acti-
vates SIRT1. Eight-week intake of vaticanol C with a HF
diet upregulates hepatic expression of PPARα-responsive
Figure 2 Distinct Effects of Resveratrol, ε-Viniferin and Vaticanol C on Activation of PPARs, Radical Scavenging Activity and SIRT1 Activa-
tion. (A) Activation of PPARα, β/δ, and γ was evaluated by cell-based transfection assays at a dose of 10 μM. Trolox, a standard antioxidant, was used 
as control. (B) Radical scavenging activity was evaluated by the DPPH method. Each result is expressed as the equivalent per mole of trolox from the 
percentage decrease with respect to the negative control values. (C) SIRT1 activation in vitro was evaluated by the Fluor de Lys fluorescence assay. 
DMSO was used as a negative control and also as a solvent for resveratrol and its derivatives to a final concentration of 100 μM in the assay buffer.
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Figure 3 Induction of PPAR-dependent Genes by Vaticanol C and Fenofibrate. (A) mRNA levels of the indicated genes were measured by RT-
qPCR in liver and skeletal muscle from WT (open column) and PPARα-knockout (closed column) mice fed a HF diet containing 60% energy as fat, sup-
plemented with vaticanol C (0 and 0.04%) for 8 weeks. Results are presented as means ± S.D. (n = 4~7). * compared with the value of 0% vaticanol C 
(*, P < 0.05, **, P < 0.01). # compared with the value of the corresponding wild-type mice (#, p < 0.05, ##, p < 0.01).(B) mRNA levels of the indicated 
genes were measured by RT-qPCR in liver from WT fed a HF diet containing 60% energy as fat, supplemented with fenofibrate (0 and 0.02%) for 4 
weeks. Results are presented as means ± S.D. (n = 4). * compared with the value of 0% fenofibrate (*, P < 0.05, **, P < 0.01).
A  
 
 
B 
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genes and skeletal muscle expression of PPARβ/δ-respon-
sive genes in wild-type but not PPARα-knockout mice.
These findings indicate that activation of PPARα and
PPARβ/δ by vaticanol C is a novel mechanism that may
afford beneficial effects against cardiovascular disease.
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